Actively Recruiting
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Led by Zagazig University · Updated on 2025-06-12
162
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
CONDITIONS
Official Title
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with multiple, recalcitrant, or non-recalcitrant common warts at different sites, sizes, and durations
- Patients may have distant lesions
- Patients of any gender aged 9 years or older
You will not qualify if you...
- Pregnant females
- Known hypersensitivity to Candida antigen or bivalent HPV vaccine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Reham Essam
Zagazig, Al Sharqia, Egypt, 2543
Actively Recruiting
Research Team
R
Reham Essam, MD
CONTACT
R
Reham Essam, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here